CRVS 241220 16.00P (CRVS241220P16000) Stock Options, News & Quotes

US OptionsDetailed Quotes

CRVS241220P16000

Watchlist

9.50
0.000.00%

15min DelayTrading Dec 17 12:01 ET

0.00High0.00Low

Intraday

5D
Daily

News

Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Announces Target Price $12
Moomoo NewsDec 19 05:31 ET · Ratings
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
BenzingaDec 18 16:06 ET
Corvus Pharmaceuticals Tumbles Despite Upbeat Comments From CEO -- Market Talk
WSJDec 18 13:49 ET
Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?
BenzingaDec 18 13:23 ET
Corvus Falls After Early-stage Data for Eczema Therapy
Seeking AlphaDec 18 08:43 ET
Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
BenzingaDec 18 08:42 ET

Comments

seer84

22 hours ago

$Nukkleus (NUKK.US)$
day 2, though im making 1k+ from this NUKE everyday… im just covering loss from pharma… never gonna touch meds again else wld be up 6k+ hahahaha

Share Your Profit/Loss

seer84

Dec 18 07:17

$Corvus Pharmaceuticals (CRVS.US)$
why everyone are leaving? i thought this is a promising clinical sign???

Trytosaveabit

Dec 18 06:37

Here it is!

$Corvus Pharmaceuticals (CRVS.US)$ Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Data from lowest dose level cohorts demonstrate a favorable safety and efficacy profile
Data includes complete results from cohort 1 and initial results from cohort 2
Early exercise of common stock warrants from stockholder generates cash proceeds of approximately $12.7 million
Company to host conference call and webca...

Trytosaveabit

Dec 17 17:11

Reminder for tomorrow

$Corvus Pharmaceuticals (CRVS.US)$ Corvus Pharmaceuticals to Announce Interim Data From Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024